Lindell Busciglio, MD
Infectious Disease · Tampa, FLNPI 1558344184
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Viiv Healthcare Company at 57.8% of the total. 2025 is the largest year on record at $8,572, 7.8 times the $1,097 reported in 2019.
Across 377 payments — averaging $40.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$9K
- Gilead$2K
- Insmed, Inc.$1K
- Merck$658
- Shionogi Inc$496
- Melinta Therapeutics, LLC$454
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$6,82545%
- Food & beverage$7,88552%
- Education$4993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 96 | $8,791 |
| Gilead | 78 | $1,618 |
| Insmed, Inc. | 39 | $1,356 |
| Merck | 38 | $658 |
| Shionogi Inc | 19 | $496 |
| Melinta Therapeutics, LLC | 24 | $454 |
| Astellas Pharma US Inc | 12 | $436 |
| Paratek Pharmaceuticals, Inc. | 12 | $292 |
| AbbVie(2 entities) | 13 | $262 |
| Johnson & Johnson | 13 | $194 |
| Theratechnologies Inc. | 7 | $142 |
| CSL Behring | 4 | $80 |
| La Jolla Pharmaceutical Company | 3 | $63 |
| Ferring Pharmaceuticals Inc. | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $54 |
| Pfizer | 3 | $51 |
| VBI Vaccine (delaware) Inc. | 2 | $37 |
| Hologic Sales And Service, LLC | 1 | $25 |
| AstraZeneca | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $22 |
| Napo Pharmaceuticals Inc | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $18 |
| Vyera Pharmaceuticals, LLC | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Smith+Nephew | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,208 in reported general payments places this provider in the 85th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JulucaDolutegravir/Rilpivirine | 150 | $507,836 |
| DovatoDolutegravir Sodium/Lamivudine | 153 | $458,956 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 85 | $319,195 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 60 | $232,465 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 55 | $214,620 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 11 | $168,656 |
| PrezcobixDarunavir/Cobicistat | 64 | $151,581 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 34 | $136,358 |
| TivicayDolutegravir Sodium | 58 | $128,096 |
| DescovyEmtricitabine/Tenofov Alafenam | 54 | $119,262 |
| CabenuvaCabotegravir/Rilpivirine | 18 | $115,321 |
| RukobiaFostemsavir Tromethamine | 13 | $115,252 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $61,341 |
| Daptomycin | 25 | $29,023 |
| ErtapenemErtapenem Sodium | 49 | $28,768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyJuluca, Dovato, Triumeq, Tivicay, Cabenuva | $8,791 | $1,540,081447 claims |
| GileadBiktarvy, Genvoya, Descovy | $1,618 | $488,084148 claims |
| Insmed, Inc.Arikayce | $1,356 | $168,65611 claims |
| Johnson & JohnsonPrezcobix | $194 | $151,58164 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $54 | $61,34112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Tampa
- Sally AlrabaaTampa$250K
- Beata CasanasTampa$227K
- Michael DunnTampa$45K
- Brahm SegalTampa$31K
- Margarita CancioTampa$23K
- Pamela NoelTampa$22K
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
- Charlotte-Paige RolleOrlando$619K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.